CDKN2A and B-cell chronic lymphocytic leukemia: Other contributors of acquired resistance to venetoclax in CLL have been identified using whole-exome sequencing of samples from CLL patients relapsing early during venetoclax therapy, including homozygous deletions of CDKN2A/B and BTG1 mutations [110].